New vaccine targets common food poisoning bug
NCT ID NCT05500417
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new vaccine (CJCV2) designed to protect against Campylobacter infection, a leading cause of foodborne illness. Fifty-nine healthy adults received three different doses of the vaccine, with or without an immune-boosting adjuvant (ALFQ). The main goal was to check safety and see how well the vaccine triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Campylobacter jejuni conjugate vaccine (CJCV2) with or without Army Liposome Formulation containing QS-21 (ALFQ) adjuvant
- What this could lead to
- If successful, this could lead to a vaccine that prevents Campylobacter infection, a common cause of food poisoning.
- What could go wrong
- This is a very early Phase 1 trial with only 59 healthy adults, focused on safety and immune response. It is too soon to know if the vaccine will actually prevent infection in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CAMPYLOBACTER INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229-3039, United States